MEDI ASSIST HEALTH SERVICESMedi Assist Healthcare Services Limited is a health-tech and insurance-tech company that manages health benefits for employers, retail members, and public health schemes, primarily serving insurance companies.
Company provides third-party administration (TPA) services to insurance companies through its wholly-owned Subsidiaries, Medi Assist TPA, Medvantage TPA, and Raksha TPA. A third-party administrator is an organization that processes health insurance claims for insurance companies and provides services such as policy administration, customer service, and network management, among others.
As of 2023, company collaborated with 35 insurance companies in India and globally. In FY23, company managed a CAGR of 35.67%. The group accounts portfolio as a percentage of revenue from contracts with customers was 72.19% and the retail portfolio was 10.98%.
Company also acts as a facilitator between (a) insurance companies and their policyholders, (b) insurance companies and healthcare providers (such as hospitals), and (c) the Government and beneficiaries of public health schemes.
Company serviced over 9500 group accounts across sectors to help administer the insurance requirements of their employees. It held a significant share of the total health insurance market for group accounts, representing 26.39% of India’s overall group health insurance market in FY23.
Company also services individual insurance policyholders, and for FY23 it managed Rs 17.57 billion of premiums for the retail health insurance market, representing 5.06% of the overall retail health insurance market in India.
In H1FY24, company helped settle 3.05 million claims, comprising 1.37 million in-patient claims and 1.68 million domiciliary or out-patient claims.
Medi assist also facilitates other healthcare and ancillary services such as hospitalization services, call center services, customer relations and contract management services, billing services, and claims processing services through its Company and other Subsidiaries, IHMS, Mayfair India, Mayfair UK, Mayfair Group Holding, Mayfair Philippines, and Mayfair Singapore.
Company has developed a pan-India healthcare provider network, which comprises 18,754 hospitals across 1,069 cities and towns and 31 states (including union territories) in India and a network across 141 countries globally, as of 2023. Company intends to pursue acquisition opportunities to expand its existing service offerings, increase market share in existing markets, and expand to new geographies. In the last eight years, company has completed several acquisitions, including the acquisition of Dedicated Healthcare Services TPA (India), Medicare Insurance TPA Services (India), IHMS, Mayfair India, Medvantage TPA, and Raksha Health Insurance TPA.
Financial Performance:
- Total premiums under management administered by the company was at Rs. 19,050 crores as of March 31, 2024, showing a growth of 30.7% over the previous year.
- Group segment fund was Rs. 16,709 crores, with a growth of 30.4% year-on-year.
- Retail segment stood at Rs. 2,341 crores, showing a growth of 33.2% year-on-year.
- Company's share of the total health insurance industry premium was at 19.6%, with a growth of 186 basis points over the previous year.
Operational Highlights:
- Maintained group account retention at 94.7%.
- Processed 3.6 million outpatient claims in the last year.
- Won an award for "Best use of AI in Healthcare" for the Fraud Detection Engine.
- Continuing to invest in preventing fraud, waste, and abuse in the system.
- Building a team of data scientists for better data security and analytics.
Financials:
- Total income for the quarter ended March 31, 2024, was Rs. 171 crores, showing a growth of 23% year-on-year.
- EBITDA for the quarter was INR 37 crores, with a margin of 22% on operating revenue.
- Profit after tax stood at Rs. 25 crores, showing a growth of 50% year-on-year.
- Total income for the year ended March 2024 was Rs. 653 crores, with a growth of 26% over the previous year.
- EBITDA for the year was Rs. 133 crores, with a margin of 21% on the operating revenue.
- Profit for the period, adjusting for exceptional items, was Rs. 92 crores, showing a growth of 22% year-on-year.
Technology and Investment:
- Investing around 3-4% of revenues every year in technology.
Total investment in the platform and capitalization as of March 31, 2024, was Rs. 10 crores.
- Investing in a platform for the UK, with an expected cost of around 8 crores.
Future Outlook:
- Expecting to bring the acquisitions to the company's margin profile in the next 2-3 quarters.
- Focused on enhancing insurer relationships and expanding benefits in the retail segment.
- Cashless facility being expanded to non-network hospitals for emergency access.
- Strong emphasis on technology for service delivery and customer retention.
Challenges and Opportunities:
- Opportunities seen in expanding the retail market share and leveraging technology for growth.
- Optimistic outlook expressed by the management regarding future prospects and growth potential.
Healthcare
Dr Lal Pathlabs Ltd| Diagnostics momentum StocksDr Lal Pathlabs Ltd| Diagnostics momentum Stocks
Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services .
Financial: Strong
Market Cap = 21,675 Cr. ROCE = 18.2 % ROE = 15.0 %
Debt to equity =0.17 Promoter holding = 54.6 % Piotroski score = 6.00
Sales growth 3Years = 14.9 % Profit Var 3Yrs = 1.81 % Return on assets = 10.2 %
Dr lal is now in strong momentum diagnostics stock. you can add in your watchlist and research on it.
Note: I am not SEBI registered financial Adviser. I solely present my views on chart .I do not charge any kind of service. This is not buy sell recommendation.
If you like my ideas than like boost and follow me for more ideas.
Thanks and comment freely
Thyrocare Technologies in Buying Zone with Strong Sales GrowthNSE:THYROCARE Thyrocare Technologies has shown a strong breakout after a long period of consolidation, supported by robust sales growth and consistent profitability. The stock is in a buying zone with strong volume, presenting a promising opportunity for investors.
Fundamentals:
Strong sales growth
Good dividend player
Consistent profitable growth
Technical:
Strong volume peak after consolidation, indicating potential buying interest
Stock is in a buying zone
May retest, so consider buying in small lots
Good liquidity
Bullish Head and Shoulders Pattern in Lal Path lab.The head and shoulders pattern is a popular technical analysis pattern that typically indicates a reversal of a bullish trend. Here's how it typically appears:
- **Head and Shoulders Pattern**:
- **Shoulders**: There are two peaks (shoulders) nearly equal in height with a higher peak (head) between them.
- **Neckline**: A trendline drawn connecting the lows of the troughs between the peaks (shoulders).
- **Volume**: Generally, volume tends to decrease as the pattern develops, with a noticeable increase at the breakout point.
- **RSI**: RSI (Relative Strength Index) often shows a divergence where the second shoulder forms, indicating weakening bullish momentum.
Description:
- **Monthly Chart**: The pattern spans over a longer time frame, suggesting a significant potential reversal.
- **Good Volumes**: Volume confirms the pattern's validity, ideally showing higher volume at the formation of the head and the breakout.
- **RSI Above 58 and Rising**: RSI being above 58 and rising suggests increasing bullish momentum, supporting the potential reversal indicated by the pattern.
- **Above Key EMA Levels**: Trading above key Exponential Moving Average (EMA) levels further reinforces bullish sentiment.
This combination of factors indicates a potentially strong head and shoulders pattern on the monthly chart of Lal Path Labs, suggesting a reversal from a bullish trend to a bearish one. Traders often look for confirmation through a decisive break below the neckline to validate this pattern. Always consider other technical and fundamental factors before making trading decisions.
Bullish Head and Shoulders Pattern in Lal Path Lab.The head and shoulders pattern is a popular technical analysis pattern that typically indicates a reversal of a bullish trend. Here's how it typically appears:
- **Head and Shoulders Pattern**:
- **Shoulders**: There are two peaks (shoulders) nearly equal in height with a higher peak (head) between them.
- **Neckline**: A trendline drawn connecting the lows of the troughs between the peaks (shoulders).
- **Volume**: Generally, volume tends to decrease as the pattern develops, with a noticeable increase at the breakout point.
- **RSI**: RSI (Relative Strength Index) often shows a divergence where the second shoulder forms, indicating weakening bullish momentum.
Description:
- **Monthly Chart**: The pattern spans over a longer time frame, suggesting a significant potential reversal.
- **Good Volumes**: Volume confirms the pattern's validity, ideally showing higher volume at the formation of the head and the breakout.
- **RSI Above 58 and Rising**: RSI being above 58 and rising suggests increasing bullish momentum, supporting the potential reversal indicated by the pattern.
- **Above Key EMA Levels**: Trading above key Exponential Moving Average (EMA) levels further reinforces bullish sentiment.
This combination of factors indicates a potentially strong head and shoulders pattern on the monthly chart of Lal Path Labs, suggesting a reversal from a bullish trend to a bearish one. Traders often look for confirmation through a decisive break below the neckline to validate this pattern. Always consider other technical and fundamental factors before making trading decisions.
MEDANTA (Global Health Ltd.)Global Health Ltd.. Riding the stairs . Heading to base 3
Best Buy : @530 After breakout of the box or @500 if found near the trendline.
Stop loss : 498 or Below Trend line
Targets: 555/580/600/620++++
Note:
''This idea is only for educational purpose,
Please Trade at your own RISK''..
THANKS.
RAINBOW CHILDRENS - Swing Trade Analysis - 5th MayRAINBOW CHILDRENS MEDICARE (1D TF) - Swing Trade Analysis given on 5th May, 2024
Pattern: CUP & HANDLE BREAKOUT
- Daily Resistance Breakout - Done ✓
- Volume Buildup at Resistance - Done ✓
- Demand Zone Retest & Consolidation - In Progress
* Disclaimer
Pharma Sector takes LEADERSHIP!Attached: Nifty Pharma Daily Chart as of 26th June 2023
- Today Price has triggered another Breakout closing above the Green Trendline and thus activating a Fresh Up Leg for the Pharma Sector and Stocks alike
- This is the 2nd Breakout Trigger (marked by arrow) and the 1st Breakout Trigger was the activation of the Cup & Handle Pattern for which Price is yet to meet its Pending Upside Target
- Pharma Index was also the TOP Sector Gainer today
- Technical Indicators such as RSI, MACD also confirm the same presence of a Strong Up Trend
Therefore, if you want to play LONGs in this Market then you must shift all your Focus on Pharma Stocks from here on, I have already shared one of them NSE:PGHH in my related ideas
POLYMED - Trading opportunity is discovered - Swing TradePOLYMED is trading at weekly & Daily Demand zone, This demand zone is also visible in lower Timeframes.
We can see that the selling volume is decreasing, so we can set our stop loss below the support zone and plan our trade accordingly.
I can conclude that this is a trade with Low Risk & High Reward.
If this analysis is useful to you then please like it & follow me for such analysis and and let me know what you think about this analysis in the comment box below.
AMRUTANJAN AT SUPPORTVanakkam Makkale. Amrutanjan bounced back from support of the trendline so expecting good upside from the scrip. But as i always say whatever we do must follow risk rewrad and money management. I personally lokoking to enter at lower levels according to market condition because dont forget that market is in bear territory. Have a profitable trade.
Comments your thoughts below and have any questions means kindly type below.
Thank you for following.
Alkem Chart Analysis !! 📈 Alkem Lab Ltd. 📉
Today broke out from a Resistance Zone after testing two times and also broke out from a downtrending Trendline Zone on closing basis.
On Buy Side I am looking for Targets of 3750-3800 zone followed by 4000-4050 zone.
StopLoss should be kept in 3375-3425 zone.
It offers 1:4 Risk To Reward.
All Important Supports and Resistances are drawn in chart. All levels are on closing basis.
Please have a look and revert back if you need some more study on it.
Disclaimer : Consult Your Financial Advisor Before Taking Any Decision On This Analysis.